These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Monoclonal anti-IgG autoantibodies derived from lipopolysaccharide-activated spleen cells of 129/Sv mice. Van Snick JL; Coulie P J Exp Med; 1982 Jan; 155(1):219-30. PubMed ID: 6976413 [TBL] [Abstract][Full Text] [Related]
10. Dynamic conformations compared for IgE and IgG1 in solution and bound to receptors. Zheng Y; Shopes B; Holowka D; Baird B Biochemistry; 1992 Aug; 31(33):7446-56. PubMed ID: 1387320 [TBL] [Abstract][Full Text] [Related]
11. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. Canfield SM; Morrison SL J Exp Med; 1991 Jun; 173(6):1483-91. PubMed ID: 1827828 [TBL] [Abstract][Full Text] [Related]
12. Proton nuclear magnetic resonance studies of human immunoglobulins: conformation of the hinge region of the IgG1 immunoglobulin. Arata Y; Honzawa M; Shimizu A Biochemistry; 1980 Oct; 19(22):5130-5. PubMed ID: 6257277 [TBL] [Abstract][Full Text] [Related]
13. Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells. Lobo PI; Patel HC Immunol Cell Biol; 1997 Jun; 75(3):267-74. PubMed ID: 9243292 [TBL] [Abstract][Full Text] [Related]
14. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Leatherbarrow RJ; Rademacher TW; Dwek RA; Woof JM; Clark A; Burton DR; Richardson N; Feinstein A Mol Immunol; 1985 Apr; 22(4):407-15. PubMed ID: 4033665 [TBL] [Abstract][Full Text] [Related]
15. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058 [TBL] [Abstract][Full Text] [Related]
16. Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I. Lund J; Takahashi N; Popplewell A; Goodall M; Pound JD; Tyler R; King DJ; Jefferis R Eur J Biochem; 2000 Dec; 267(24):7246-57. PubMed ID: 11106438 [TBL] [Abstract][Full Text] [Related]
17. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310 [TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo. Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311 [TBL] [Abstract][Full Text] [Related]
20. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD MAbs; 2015; 7(1):84-95. PubMed ID: 25524268 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]